Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection

Clinical Infectious Diseases

Volumn 51, Issue 6, 2010, Pages 641-650

  Corey, G Ralph ^a   Wilcox, Mark ^d   Talbot, George H ^b,e   Friedland, H David ^b   Baculik, Tanya ^b   Witherell, Gary W ^b   Critchley, Ian ^b   Das, Anita F ^c   Thye, Dirk ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b Cerexa Inc   (United States)

^c AxiStat Inc   (United States)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e Talbot Advisors   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CEFTAROLINE; PLACEBO; VANCOMYCIN;

ADULT; AGED; ARTICLE; BACTEREMIA; BITE INFECTION; BURN INFECTION; CELLULITIS; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COOMBS POSITIVE HEMOLYTIC ANEMIA; COOMBS TEST; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HUMAN; HYPOKALEMIA; INSOMNIA; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN ABSCESS; SKIN INFECTION; SKIN STRUCTURE; THROMBOCYTOPENIA; TREATMENT OUTCOME; ULCER INFECTION; VOMITING; WOUND INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZTREONAM; CEPHALOSPORINS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; SKIN DISEASES, BACTERIAL; TREATMENT OUTCOME; VANCOMYCIN; YOUNG ADULT;

EID: 77955957827     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/655827     Document Type: Article

References (37)

1. Ho RC, Ho EC, Mak A. Cutaneous complications among i.v. buprenorphine users. J Dermatol 2009; 36:22-29.
2. Lamagni TL, Darenberg J, Luca-Harari B, et al. Epidemiology of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol 2008; 46: 2359-2367.
3. Lamagni TL, Neal S, Keshishian C, et al. Severe Streptococcus pyogenes infections, United Kingdom, 2003-2004. Emerg Infect Dis 2008; 14: 202-209.
4. Moet GJ, Jones RN, Biedenbach DJ, et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 2007; 57:7-13.
5. Rennie RP, Jones RN, Mutnick AH; SENTRY Program Study Group (North America). Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 2003; 45:287-293.
6. Chang CM, Lee HC, Lee NY, et al. Community-acquired Klebsiella pneumoniae complicated skin and soft-tissue infections of extremities: emphasis on cirrhotic patients and gas formation. Infection 2008; 36: 328-334.
7. Grundmann H, Aires-de-Sousa M, Boyce J, et al. Emergence and resurgence of methicillin-resistant Staphylococcus aureus as a publichealth threat. Lancet 2006; 368:874-885.
8. Nubel U, Roumagnac P, Feldkamp M, et al. Frequent emergence and limited geographic dispersal of methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci U S A 2008; 105:14130-14135.
9. Moran GJ, Krishnadasan A, Gorwitz RJ, et al; EMERGEncy ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666-674.
10. Tillotson GS, Draghi DC, Sahm DF, et al. Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-2007: laboratory-based surveillance study. J Antimicrob Chemother 2008; 62:109-115.
11. LoVecchio F, Perera N, Casanova L, et al. Board-certified emergency physicians' treatment of skin and soft tissue infections in the community- acquired methicillin-resistant Staphylococcus aureus era. Am J Emerg Med 2009; 27:68-70.
12. Napolitano LM. Early appropriate parenteral antimicrobial treatment of complicated skin and soft tissue infections caused by methicillinresistant Staphylococcus aureus. Surg Infect (Larchmt) 2008; 9(suppl 1): s17-s27.
13. Sievert DM, Rudrik JT, Patel JB, et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008;46: 668-674.
14. Gracia M, Diaz C, Coronel P, et al. Antimicrobial susceptibility of Streptococcus pyogenes in Central, Eastern, and Baltic European Countries, 2005 to 2006: the cefditoren surveillance program. Diagn Microbiol Infect Dis 2009; 64:52-56.
15. Liu X, Shen X, Chang H, et al. High macrolide resistance in Streptococcus pyogenes strains isolated from children with pharyngitis in China. Pediatr Pulmonol 2009; 44:436-441.
16. Montagnani F, Stolzuoli L, Croci L, et al. Erythromycin resistance in Streptococcus pyogenes and macrolide consumption in a central Italian region. Infection 2009; 37:353-357.
17. Richter SS, Heilmann KP, Beekmann SE, et al. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis 2005; 41:599-608.
18. Malhotra-Kumar S, Van Heirstraeten L, Lammens C, et al. Emergence of high-level fluoroquinolone resistant in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin. J Antimicrob Chemother 2009; 63:886-894.
19. Broyles LN, van Beneden C, Beall B, et al. Population-based study of invasive disease due to ß-hemolytic streptococci of groups other than A and B. Clin Infect Dis 2009; 48:706-712.
20. Ge Y, Biek D, Talbot GH, Sahm DF. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008; 52:3398-3407.
21. Iizawa Y, Nagai J, Ishikawa T, et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother 2004; 10:146-156.
22. Jacqueline CJ, Caillon V, Le Mabecque AF, et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin- intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 2007; 51:3397-3400.
23. Mushtaq S, Warner M, Ge Y, et al. In vitro activity of ceftaroline (PPI- 0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007; 60:300-311.
24. Sader HS, Fritsche TR, Jones RN. Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52:1153-1155.
25. Talbot GH, Thye D, Das A, et al. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007; 51:3612-3616.
26. Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference of non-unity relative risk. Stat Med 1990; 9:1447-1454.
27. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213-226.
28. Frazee BW, Lynn J, Charlebois ED, et al. High prevalence of methicillinresistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med 2005; 45:311-320.
29. Kaplan SL, Hulten KG, Gonzalez BE, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005; 40:1785-1791.
30. Miller LG, Perdreau-Remington F, Bayer AS, et al. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillinsusceptible S. aureus infection: a prospective investigation. Clin Infect Dis 2007; 44:471-482.
31. Moran GJ, Amii RN, Abrahamian FM, et al. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis 2005; 11:928-930.
32. Young DM, Harris HW, Charlebois ED, et al. An epidemic of methicillin- resistant Staphylococcus aureus soft tissue infections amongmedically underserved patients. Arch Surg 2004; 139:947-951.
33. Sader HS, Fritsche TR, Kaniga K, et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005; 49:3501-3512.
34. Hankin A, Everett WW. Are antibiotics necessary after incision and drainage of a cutaneous abscess? Ann Emerg Med 2007; 50:49-51.
35. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373-1406.
36. Noel GJ, Strauss RS, Amsler K, et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chem other 2008; 52:37-44.
37. Stryjewski ME, Graham DR,Wilson SE, et al; Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study. Telavancin versus vancomycin for the treatment of complicated skin and skinstructure infections caused by gram-positive organisms. Clin Infect Dis 2008; 46:1683-1693.